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on HIV infection in this environment, none of these
studies has addressed the association of HIV
infection with lymphoid malignancies. The dearth of
information linking HIV infection with lymphoid
malignancies in this area thus necessitated this study.
The objective of this study is to document the
incidence of HIV seropositivity in patients with
lymphoid malignancies in a tertiary centre in
Southern Nigeria.
The course of disease in 275 patients with lymphoid
malignant disorders was analyzed in a referral center
r e t rospec t i ve ly (n=201 ;1996-2003) and
prospectively (n=74;2004-2006). These were
patients attending the Haemato-Oncology and
HIV/AIDS pilot project, PEPFAR (President
Emergency Plan For AIDS Relief) at University of
Benin Teaching Hospital (UBTH), a major referral
center serving the Niger Delta region of Nigeria.
Clinicopathologic profile and demographic features
were obtained in detail. Histological analysis of
lymph node biopsies from the patients served to
establish the diagnosis of the various lymphoid
malignancies. Histopathologic classification was
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The human immunodeficiency virus (HIV) epidemic has a significant impact worldwide and
infected subjects are at increased risk of developing cancer. We aim to determine the HIV seropositivity of
lymphoid malignant patients in a tertiary centre in Southern Nigeria.
The course of disease in 275 patients with lymphoid malignant disorders at the University of Benin
Teaching Hospital, Benin City, Nigeria, was analysed from 1996 to 2006. Blood specimens screened for
antibody to HIV infection were confirmed by Western blot and the CD4+ lymphocyte count was measured by
flow cytometry technique.
Atotal of 275 patients aged 18-72years were studied. Of the 275 lymphoid malignancies 11 cases were
found to be HIV seropositive giving a seroprevalence of 4%. The most frequent lymphoid malignancy in
association with HIV seropositivity was non-hodgkin's lymphoma (NHL) with a prevalence of 4.12% over the
less frequent lymphoid neoplasms. The overall median CD4+ lymphocyte count was 185µl with 9 cases
seropositive for HIV below 200µl (P<0.0001).
We conclude that the seroprevalence of HIV infection in patients with lymphoid malignancies
was 4% with NHL being the most common neoplasm associated with HIV infection in concordance with
studies in the Diaspora.
HIV seropositivity; lymphoid malignancies.
INTRODUCTION
Human immunodeficiency virus (HIV) epidemic in
African subcontinent has a significant impact in
Nigeria and infected subjects are at increased risk of
developing cancer, particularly in the later stages of
Acquired immunodeficiency syndrome (AIDS).
Also, haematological malignancies are not
uncommon in our area. Due to inadequate diagnostic
facilities and lack of health education, they are
diagnosed at an advanced stage when treatment is
either impossible or very difficult. Following the
outbreak of HIV infection in 1981 there has been a
widespread increase in the incidence of HIV-
associated malignancies including non-Hodgkin's
lymphoma (NHL), kaposi sarcoma and squamous
cell carcinoma of the cervix. It has been suggested
that HIV may indirectly encourage the development
of malignancies by initiating the release of cytokines
which stimulate B-cell proliferation. The
continuous stimulus to B-lymphocytes may permit
mutations in critical oncogenes or tumour
suppressor genes, eventually resulting in malignant
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Table 1:
Table 2:
Viruses are aetiologically linked to approximately
20% of all malignancies worldwide and HIV
accounts for a significant cancer burden. Lymphoid
malignancies have been reported to be on the increase
since the outbreak of HIV infection. It is still not
clear why HIV infected subjects have a predisposition
for mainly B-lineage derived malignancies; though
multifactorial reasons have recently been
suggested. However, improved diagnostic
techniques, effects of the HIV epidemic,
immunosuppressive therapies have been reported to
account for only one-third of this increase. The
most frequent lymphoid malignancy in association
with HIV seropositivity was NHL with a prevalence
of 4.12% over the less frequent lymphoid neoplasms.
The predominance of the NHL tumour in this study
was obvious. This is similar to the findings in
Baltimore, USA and Siriraj hospital, Thailand.
Although there has been a rising trend of AIDS
associated NHL worldwide, in the developing
countries, the risk appears to be much lower as
observed in previous studies. This may be
The Prevalence, Age and Sex Distribution
of Patients with Lymphoid Malignancies and HIV
Seropositivity.
Histopathological Profile and CD4+









done according to the modern system of
International Working Formulation. Recordings of
peripheral blood film and bone marrow aspiration
cytology and trephine biopsy were taken. Blood
specimens were screened for antibody to HIV
infection using ELISA technique and confirmed by
Western Blot while the CD4+ lymphocyte count was
measured by the Partec IVD Flow-Cytometry based
technique.
A total of 275 patients with a diagnosis of lymphoid
malignancy aged 18-72 years with a median age of
45 years over an 11-year period were reviewed. This
comprised 170 (61.8%) NHL patients, 60(21.8%)
chronic lymphocytic leukaemia (CLL) patients,
35(12.7%) Hodgkin's lymphoma (HL) patients and
10(3.6%) acute lymphoblastic leukaemia (ALL)
patients based on confirmed histological
examination of excised lymph nodes and bone
marrow aspiration cytology. These were 92 males
(33.5%) and 183 females (66.5%) with a male-to-
female ratio of 1:2. The overall median age for NHL,
HL, CLL and ALL was 39, 33, 56 and 24 years
respectively.
Of the 275 lymphoid malignancies, 11 cases were
found to be HIV seropositive. These include
7(2.55%) NHL, 2(0.73%) CLL and one each
(0.36%) for HL andALL patients respectively. These
11 cases consist of 5 males (45.5%) and 6 females
(54.5%) with a mean age of 42±12.7 years (range,
20-59 years). Seven (4.12%) of 170 NHL cases,
2(3.33%) of 60 CLL cases and 1 each of the 35
(2.86%) HL and 10 (10%) ALL cases encountered
were confirmed seropositive for HIV antibody (table
1). Baseline characteristics of study patients revealed
that performance status (PS) as assessed according to
the Eastern Cooperative Oncology Group (ECOG)
scale had all the patients within the worst scale (2-4).
Among the lymphoid malignancies with HIV
seropositivity, NHL was the most frequent.
Seropositivity was observed in 3 patients each with
high and intermediate grade lymphoma and only one
case with low grade lymphoma (table 2). The Binet
Clinical staging system showed that the 2 CLL
seropositive patients presented in advanced stages B
and C. The haematological blood findings showed
various degrees of cytopenias. The overall median
CD4+ lymphocyte count was 185µl with 9cases
seropositive for HIV below 200µl (P<0.0001). The
median CD4+ lymphocyte count for high grade and
intermediate grade lymphoma was 150µl and 192µl
respectively (P=0.04). The median survival of the
series is 4 months in comparison to 9 months for
patients with lymphoid malignancies who were
seronegative for HIV. As at the time of writing this
report, only one of the NHL-HIV patients was alive
as they presented in advanced stage of the disease.
They died of complications arising from HIV
infection (n=3) while the others (n=7) died of disease





attributed to lack of investigative facilities and
earlier death from AIDS manifestations. The HIV
infected patients had predominantly high and
intermediate grade (diffuse large cell) lymphoma, a
finding consistent with other previous studies.
Unlike the NHL-HIV infection which was
predominant in this study and other previous studies,
there was a high incidence of non-AIDS defined
cancers reported in HIV infected subjects in
Germany when compared to the general
population. The paucity of follicular type of NHLin
this study may be due to the late presentation of
diseases, ignorance and poverty including other
strong limiting factors. With the improving survival
of AIDS patients however, there may well be an
increase in new discovery of non-AIDS related
malignancies.
The other less frequent lymphoid malignancies
found associated with HIV infection were CLL
(3.33%), HL (2.86%) and ALL (10%). The apparent
high percentage for ALL may be due to the small
number of diagnosed ALL patients within the study
period. Over the past 2 decades it has been reported
that the CLL-HIV infection has significantly
increased. This may be related to the different age
ranges for CLL and HIV infections. Unlike NHL,
HL-HIV infection rarely develops and its
characteristics are not well defined. In a Cooperative
Study Group of malignancies associated with HIV
infection, it was reported that HL is not an AIDS-
defining disease. The only HL patient associated
with HIV seropositivity in this study had mixed
cellularity histology similar to previous studies with
an atypical aggressive clinical course resulting in
early death within few months of first
presentation. All the lymphoid neoplastic-HIV
infected patient population presented within the
worst PS scale (2-4) which is typical of our cancer
patients in this environment.
Despite the advent of HAART, malignancy is a
leading cause of morbidity and mortality since HIV
infection presents additional challenges to
management. Majority of the patients were treated
with systemic chemotherapy combined with
HAART since they usually presented at advanced
stage of disease. Hence, treatment decisions for
AIDS-related malignancies are guided largely by the
presence and extent of symptomatic disease.
Anaemia was a common finding and this is usually
due to the chronic disease but rarely due to
haemolysis secondary to high fever. Standard
chemotherapy for cancer patients which is intensive
may not be appropriate in the HIV setting as these
patients often have decreased immune status which
is further worsened by high risk of infectious
complications.
Trea tment re la ted toxic i t i es espec ia l ly







Inadequate supportive care, occasional lack of
cytotoxic drugs and absence of modern facilities for
therapy combined to make the disease outcome worse
than expected. Even with the immune restoration
afforded by HAART, low-dose chemotherapy was
safely administered to some of the patients because of
the myelosuppressive effects of cytotoxic drugs,
which might have caused further immune
suppression. This implies that one may not get the
desired cytoreduction of the tumour-hence the
challenges involved. Although optimal treatment of
these neoplasms is at present uncertain, recent
advances in chemotherapy, ARV drugs and
supportive care protocols are allowing for more
aggressive management of many AIDS-related
cancers.Improved outcome with combination
chemotherapy have been reported in the highly active
antiretroviral therapy (HAART) era but results are
still inferior compared to those HIV seronegative
patients with lymphoid malignancies. All the HIV
seropositive patients received HAART regimen
combination of Stavudine 40mg bid, Lamivudine
150mg bid and Nevirapine 200mg daily for 2weeks
and then bid.
In conclusion, the seroprevalence of HIV infection in
patients with lymphoid malignancies was 4.12%. Of
the 11 HIV seropositive lymphoid malignant patients,
NHL was the most common neoplasm associated
with HIV infection in Black race in concordance with
studies in the Diaspora.
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